Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Krystal Biotech Inc
KRYS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$313.66
2.16
0.69%
Últ. Act.: Oct 26, 4:02 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 6 días de ahora en lun nov 2nd, antes de la apertura del mercado
Conferencia telefónica:
Conferencia telefónica programada para dentro de 6 días a las 8:30 a. m.
Haz clic para ver el webcast
Krystal Biotech Financials
Krystal Biotech (KRYS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of $1.29 per share from the
Benzinga Newsdesk
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.
Avi Kapoor
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 by 31.65 percent. This is a 52.5 percent increase over earnings of $1.20 per share from the
Benzinga Newsdesk
Krystal Biotech: Q4 Earnings Insights
Benzinga Insights
PRO
Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.39 by 22.21 percent. This is a 11.84 percent increase over earnings of $1.52 per share from the
Benzinga Newsdesk
